Ulcerative Colitis study: Selenium supplementation
Official title Selenium Supplementation in Moderate-Severely Active Ulcerative Colitis Patients Treated With Advanced Therapies
ClinicalTrials.gov ID: NCT07427017
What this study is testing
What is Selenium supplementation?
An investigational daily oral supplement being studied for ulcerative colitis
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study wants to see if taking selenium can improve how well patients with active ulcerative colitis respond to biologic or small‑molecule treatments.
- Who it's for
- Adults with moderate or severe ulcerative colitis who are already receiving advanced therapies.
- What's involved
- Participants will receive selenium supplements and have regular clinic visits and tests to monitor their disease and treatment response.
- Time commitment
- The trial lasts several months, with scheduled visits and blood tests throughout the study period.
- Phase 2: a mid-size study of how well it works
- You might receive a placebo (an inactive treatment) instead of the study drug.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 85
You may be able to join if
- Known or newly diagnosed moderate to severe UC (as defined by the modified Mayo score of 5-9
- The acceptable list of advanced therapies is (anti-TNF, anti-IL23, anti-integrin).
- Mayo endoscopic sub-score ≥2 (moderate to severe)
- Mayo rectal bleeding sub-score ≥1 (moderate to severe)
- Mayo stool frequency sub-score ≥2 (moderate to severe)
You likely can't join if
- Pediatric patients defined by being younger than 18 years of age
- Patients who are currently pregnant, expecting to participate in getting pregnant during the study period through natural or assisted techniques...
- Women with childbearing potential will be required to use highly effective birth control if not surgically sterile or postmenopausal for ≥ 2 years...
- The criteria for being considered postmenopausal would be the following: twelve months of spontaneous amenorrhea or
- Male people are considered of reproductive potential unless surgically sterile (e.g., vasectomy) and should not participate in activities of...
- If participants become pregnant during the intervention period, they will be withdrawn to avoid risks to the fetus.
See the full eligibility criteria
- Known or newly diagnosed moderate to severe UC (as defined by the modified Mayo score of 5-9; confirmed by clinical, endoscopic, and/or histopathological evidence prior to screening as per standard of care) who are...
- The acceptable list of advanced therapies is (anti-TNF, anti-IL23, anti-integrin). For example, anti-tumor necrosis factor - infliximab, adalimumab, golimumab, certolizumab
- Mayo endoscopic sub-score ≥2 (moderate to severe)
- Mayo rectal bleeding sub-score ≥1 (moderate to severe)
- Mayo stool frequency sub-score ≥2 (moderate to severe)
- Age 18-85 and able to fully participate in all aspects of the trial
- Pediatric patients defined by being younger than 18 years of age
- Patients who are currently pregnant, expecting to participate in getting pregnant during the study period through natural or assisted techniques (in-vitro fertilization, intra-uterine insemination, intracytoplasmic...
- Women with childbearing potential will be required to use highly effective birth control if not surgically sterile or postmenopausal for ≥ 2 years for the duration of the active intervention period.
- The criteria for being considered postmenopausal would be the following: twelve months of spontaneous amenorrhea or; six months of spontaneous amenorrhea with serum FSH levels 40 mIU/mL or
- Male people are considered of reproductive potential unless surgically sterile (e.g., vasectomy) and should not participate in activities of reproductive potential other than heterosexual intercourse (e.g., they should...
- If participants become pregnant during the intervention period, they will be withdrawn to avoid risks to the fetus.
- Medical conditions that may predispose to toxicity including a history of type 2 diabetes mellitus, hypothyroidism, acute or chronic kidney disease, history of kidney transplant, history of infertility.
- Abnormal baseline labs for renal function, thyroid function, or hepatic function: Renal function panel including creatinine (results should fall within normal lab reference ranges below 1.3 mg/dL for males and 1.1 mg/dL...
- Any patient taking blood thinners, cholesterol-lowering drugs, antioxidants, warfarin, or any other immune system-dependent medications that may interact with selenium.
- Allergies to components/compounds used to formulate selenium or placebo supplements.
- Known or suspected diagnosis of Crohn's colitis, indeterminate colitis, ischemic colitis, radiation colitis, diverticular disease associated with colitis, microscopic colitis or infectious colitis (Clostridium...
- Concern for impending need for hospitalization or urgent colectomy as determined by the treating provider(s) and/or investigator performing screening/evaluation for enrollment.
- Unwillingness or inability to be compliant with selenium supplementation, adjustments in diet if necessary, or complete study-related visits/biospecimen collection.
The study team makes the final eligibility decision.
Where it is enrolling
- Chicago, Illinois, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 85 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Chicago, Illinois, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.